XML 45 R37.htm IDEA: XBRL DOCUMENT
v3.25.1

Strategic License and Research and Collaboration Agreements - Additional Information (Details) £ in Millions | 1 Months Ended | 3 Months Ended |
--- | --- | --- | ---
Jan. 31, 2025 USD ($) | May 31, 2024 USD ($) | Mar. 31, 2024 USD ($) | Oct. 31, 2023 USD ($) | Feb. 28, 2022 USD ($) | Nov. 30, 2015 USD ($) | Mar. 31, 2025 USD ($) | Mar. 31, 2025 GBP (£) | Mar. 31, 2024 USD ($) | Dec. 31, 2024 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Research and development expenses |  |  |  |  |  |  | $ 52,151,000 |  | $ 45,757,000 |
Fund received upon completion of certain development milestone | $ 1,500,000 |  |  |  |  |  |  |  |  |
2015 TSRI License Agreement |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Milestones achieved |  |  |  |  |  |  | 0 |  |  |
Milestone Payments |  |  |  | $ 300,000 |  |  |  |  |  |
Accrued Royalties |  |  |  |  |  |  | $ 0 |  |  |
2015 TSRI License Agreement | Maximum |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Development and regulatory milestone payments |  |  |  |  |  | $ 1,500,000 |  |  |  |
Commercial milestone payments |  |  |  |  |  | $ 3,500,000 |  |  |  |
Amgen Research and Collaboration Agreement |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Collaboration agreement termination description |  |  |  |  |  |  | The Amgen Collaboration Agreement automatically terminated upon its third anniversary in September 2024. | The Amgen Collaboration Agreement automatically terminated upon its third anniversary in September 2024. |  |
Research and collaboration agreement quarterly payments for first two year |  |  |  |  |  |  | $ 50,000,000 |  |  |
Related party transaction obligation with related party |  |  |  |  |  |  | 6,300,000 |  |  | $ 0
Research and development expenses |  |  |  |  |  |  | 6,300,000 |  | 0 |
Amgen Research and Collaboration Agreement | Minimum |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Research and collaboration agreement quarterly payments for third year |  |  |  |  |  |  | $ 12,500,000 |  |  |
Vanderbilt Research Agreement |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Research agreement expiry date |  |  |  |  |  |  | 2023-09 | 2023-09 |  |
First Vanderbilt Research Agreement |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Research and collaboration agreement quarterly payments |  |  |  |  | $ 1,700,000 |  |  |  |  |
Second Vanderbilt Research Agreement |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Research agreement expiry date |  |  |  |  |  |  | 2025-03 | 2025-03 |  |
Second Vanderbilt Research Agreement | Maximum |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Research and collaboration agreement payments |  | $ 600,000 |  |  |  |  |  |  |  |
Parkinson's Research Ventures Funding Agreement |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Research and development expenses |  |  |  |  |  |  | $ 200,000 |  | $ 200,000 |
Payments for execution of agreement |  |  | $ 1,100,000 |  |  |  |  |  |  |
Maximum repayment amount agreed to pay. | £ |  |  |  |  |  |  |  | £ 8.4 |  |
Parkinson's Research Ventures Funding Agreement | Maximum |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |
Funds provided for preclinical research and development activities |  |  |  |  |  |  | $ 2,600,000 |  |  |

X
- Definition Collaboration agreement termination description. + References No definition available. + Details
Name: | nmra_CollaborationAgreementTerminationDescription
Namespace Prefix: | nmra_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Commercial milestone payments. + References No definition available. + Details
Name: | nmra_CommercialMilestonePayments
Namespace Prefix: | nmra_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Development and regulatory milestone payments. + References No definition available. + Details
Name: | nmra_DevelopmentAndRegulatoryMilestonePayments
Namespace Prefix: | nmra_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Fund received upon completion of certain development milestone. + References No definition available. + Details
Name: | nmra_FundReceivedUponCompletionOfCertainDevelopmentMilestone
Namespace Prefix: | nmra_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Funds provided for pre-clinical research and development activities. + References No definition available. + Details
Name: | nmra_FundsProvidedForPreClinicalResearchAndDevelopmentActivities
Namespace Prefix: | nmra_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Maximum repayment amount agreed to pay. + References No definition available. + Details
Name: | nmra_MaximumRepaymentAmountAgreedToPay
Namespace Prefix: | nmra_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Milestone Payments + References No definition available. + Details
Name: | nmra_MilestonePayments
Namespace Prefix: | nmra_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Milestones achieved. + References No definition available. + Details
Name: | nmra_MilestonesAchieved
Namespace Prefix: | nmra_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Payments for execution of agreement. + References No definition available. + Details
Name: | nmra_PaymentsForExecutionOfAgreement
Namespace Prefix: | nmra_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Related party transaction obligation with related party. + References No definition available. + Details
Name: | nmra_RelatedPartyTransactionObligationWithRelatedParty
Namespace Prefix: | nmra_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Research agreement expiry date. + References No definition available. + Details
Name: | nmra_ResearchAgreementExpiryDate
Namespace Prefix: | nmra_
Data Type: | xbrli:gYearMonthItemType
Balance Type: | na
Period Type: | duration

X
- Definition Research and collaboration agreement payments. + References No definition available. + Details
Name: | nmra_ResearchAndCollaborationAgreementPayments
Namespace Prefix: | nmra_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Research And Collaboration Agreement Quarterly Payments + References No definition available. + Details
Name: | nmra_ResearchAndCollaborationAgreementQuarterlyPayments
Namespace Prefix: | nmra_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Research and collaboration agreement quarterly payments for first two years. + References No definition available. + Details
Name: | nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForFirstTwoYears
Namespace Prefix: | nmra_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Research and collaboration agreement quarterly payments for third year. + References No definition available. + Details
Name: | nmra_ResearchAndCollaborationAgreementQuarterlyPaymentsForThirdYear
Namespace Prefix: | nmra_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details
Name: | us-gaap_AccruedRoyaltiesCurrentAndNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nmra_TwoThousandAndFifteenTsriLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nmra_AmgenResearchAndCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nmra_VanderbiltSponsoredResearchAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nmra_FirstVanderbiltSponsoredResearchAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nmra_SecondVanderbiltSponsoredResearchAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nmra_ParkinsonsResearchVenturesFundingAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |